A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy

BMC Urology

Research Article

Ninfa Satariano¹  Carmelo Tambone²  Andrea Tasca²  Enrico Scremin²  Maria Silvia Favretto³  Giampaolo Bolzicco³ 

[1] Department of Medical Physics, San Bortolo Hospital, Vicenza, Italy;Department of Urology, San Bortolo Hospital, Vicenza, Italy;Departments of Radiation Oncology, San Bortolo Hospital, Vicenza, Italy;

关键词: Androgen Deprivation Therapy;    Prostate Volume;    Localize Prostate Cancer;    Stereotactic Body Radiation Therapy;    Biochemical Failure;   

DOI  :  10.1186/1471-2490-13-49

 received in 2013-04-06, accepted in 2013-09-03,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundRadiotherapy is an increasingly preferred treatment option for localized prostate cancer, and stereotactic body radiation therapy (SBRT) a relatively established modality of therapeutic irradiation. The present study analyzes the toxicity and biochemical efficacy of SBRT in 100 consecutive prostate cancer patients treated with CyberKnife Robotic Radiosurgery System.MethodsOne hundred patients were treated with SBRT at the Radiation Oncology department of San Bortolo Hospital, Vicenza, Italy. All patients included in this IRB-approved protocol-driven prospective study had biopsy-proven prostate cancer. Risk category was low in 41, intermediate in 42, and high in 17 patients. The patients were treated with CyberKnife-SBRT (CK-SBRT), the prescription dose was 35 Gy in five fractions, corresponding to 92 Gy in 2-Gy fractions (α/β =1.5 Gy); 29 patients also received androgen deprivation therapy (ADT).ResultsMedian follow-up was 36 months (range, 6–76 months). Acute Grade 2 genitourinary and gastrointestinal toxicity occurred in respectively 12% and 18% of the patients; there were no Grade 3 or higher acute toxicities. Late Grade 1, 2, and 3 genitourinary toxicities occurred in 4%, 3%, and 1% of the patients, respectively; late Grade 1 gastrointestinal toxicity occurred in two patients and Grade 2 toxicity in one patient; no late gastrointestinal toxicities of grade 3 or 4 were observed. Median PSA nadir was 0.45 ng/ml at 36 months for all patients. In the SBRT-monotherapy group, the median PSA nadir at 36 months was 0.62 ng/ml; in the ADT-SBRT group, it was 0.18 ng/ml. Four patients had clinical recurrence: one local, two lymph nodes, and one to the bone. Ninety-six patients had no evidence of biochemical or clinical recurrence. A benign PSA bounce of median 1.08 ng/ml occurred in 12% of the 71 SBRT monotherapy patients at a mean 23 months (range, 18–30 months).ConclusionsIn this study CK-SBRT has provided promising outcomes in localized prostate cancer with good PSA response, minimal toxicity and patient inconvenience.

【 授权许可】

CC BY   
© Bolzicco et al.; licensee BioMed Central Ltd. 2013